Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Prospective, Blinded, Randomized, Placebo Controlled, International Multicenter Study to Assess the Safety and Efficacy of a Single SQ Injection of Zalunfiban in Subjects With ST-elevation MI in the Pre-hospital Setting

NCT04825743 is registered in ClinicalTrials.gov with CeleCor Therapeutics as lead sponsor.

NCT NCT04825743
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04825743 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Prospective, Blinded, Randomized, Placebo Controlled, International Multicenter Study to Assess the Safety and Efficacy of a Single SQ Injection of Zalunfiban in Subjects With ST-elevation MI in the Pre-hospital Setting
Lead sponsor
CeleCor Therapeutics
Phase
Phase 3
Overall status
Active, not recruiting
Start date
April 24, 2021
Completion date
May 13, 2026
Enrollment
2,463 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

st-elevation myocardial infarction (stemi)